title: Measles seroepidemiology among adolescents and young adults: response to revaccination.
abstract: We evaluated the seroprevalence of measles antibody and response to measles reimmunization in 590 previously vaccinated adolescents and young adults; 263 were seronegative. To differentiate between primary and secondary vaccine failure, anti-measles IgM and IgG titres were assessed again 2-4 weeks after revaccination in 144 (105 seronegative, 39 seropositive) individuals: 75 seronegative participants responded to revaccination anamnestically (P < 0.001) and developed immunity, 11 also showed IgM response (probably primary vaccine failure); 38 seropositive participants remained seroprotected without significant increase in antibody titre (P = 0.577). Primary vaccine failure was 4.7%; secondary vaccine failure was 27.1%. After revaccination, 87.3% were seroprotected.
authors.affiliation: Department of Paediatrics, Paediatric Infectious Disease Ward, Bouali-Cina Hospital, Mazandaran University of Medical Sciences, Sari, Islamic Republic of Iran. saffar@softhome.net
authors.forename: M J
authors.initials: MJ
authors.lastname: Saffar
authors.forename: M
authors.initials: M
authors.lastname: Alraza-Amiri
authors.forename: A
authors.initials: A
authors.lastname: Ajami
authors.forename: F
authors.initials: F
authors.lastname: Baba-Mahmoodi
authors.forename: A R
authors.initials: AR
authors.lastname: Khalilian
authors.forename: C
authors.initials: C
authors.lastname: Vahidshahi
authors.forename: A
authors.initials: A
authors.lastname: Shamsizadeh
mesh_terms: D000293:Adolescent; D000328:Adult; D000359:Aftercare; D000914:Antibodies, Viral / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006301:Health Services Needs and Demand; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary / Q000379:methods*; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007492:Iran / Q000453:epidemiology; D008297:Male; D008403:Mass Screening / Q000379:methods; D032541:Mass Vaccination / Q000379:methods*; D008457:Measles / Q000097:blood / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000276:immunology*; D008459:Measles virus / Q000276:immunology; D011159:Population Surveillance; D016036:Seroepidemiologic Studies; D017211:Treatment Failure
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008458:Measles Vaccine